Jason Gerberry


Leerink Swann Reiterates Optimistic View of Heron Therapeutics Inc Following Initiation of HTX-011 Phase 2 Trial

Leerink Swann analyst Jason Gerberry came out with some commentary on Heron Therapeutics Inc (NASDAQ:HRTX) following the initiation of a Phase 2 clinical trial of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts